FDA Approves First Drug for Polycythemia Vera

FDA approved Mimrylo (rusfertide) on 28 August 2026 for adults with polycythemia vera, a rare blood disorder in which the bone marrow overproduces red blood cells. It is, in FDA’s own words, the first drug of its kind approved for the disease — a hepcidin-mimetic peptide that works upstream of the standard treatment, routine phlebotomy, rather than alongside it.

What FDA approved

Polycythemia vera is a rare, chronic blood cancer in which the bone marrow makes too many red blood cells, thickening the blood and raising the risk of clots, stroke, and heart attack. The standard first-line treatment is therapeutic phlebotomy — regularly draining blood to bring red-cell counts down — sometimes paired with cytoreductive drugs. Mimrylo does not replace phlebotomy outright; in the trial that supported approval, it reduced how often patients needed it. FDA's press release frames the approval plainly: this is the first drug of its kind for polycythemia vera, opening a mechanism the disease has not had a therapy built around before.

A hormone the body already makes

Rusfertide is a synthetic mimic of hepcidin, the hormone the liver produces to control iron availability throughout the body. Iron is a rate-limiting input for red blood cell production; by mimicking hepcidin's suppressive effect on iron, rusfertide constrains the marrow's raw material rather than targeting the marrow directly. It is delivered by subcutaneous injection. The approach is a departure from polycythemia vera's existing drug classes, which work through cytoreduction or JAK-pathway inhibition — rusfertide instead intervenes in iron metabolism, the same lever the body already pulls on its own, just turned up.

What the VERIFY trial showed

• Design: Phase 3, randomized, double-blind, placebo-controlled, 293 adults with polycythemia vera who required frequent therapeutic phlebotomy.
• Primary result: 76.9% of patients on rusfertide required no phlebotomy during the weeks 20–32 assessment window, compared with 32.9% of patients on placebo.
• What it means operationally: a majority-response rate on a phlebotomy-elimination endpoint is the kind of result that reframes a chronic, appointment-heavy management routine into an injectable maintenance therapy for patients who respond.

The deal behind the approval

Protagonist Therapeutics discovered rusfertide and carried it through Phase 3 development. In April 2026, Protagonist exercised its right to opt out of commercializing the drug in the United States, transferring US regulatory and commercial responsibility to Takeda under their existing collaboration. That structure means Wednesday's approval is as much a milestone-payment trigger as a clinical one: it releases $275 million to Protagonist — a $200 million opt-out fee plus a $75 million approval milestone — with up to $875 million more available in additional milestones and tiered royalties of 14% to 29% on worldwide sales owed to Protagonist regardless of which company holds the license. For regulatory and business-development teams watching biotech licensing structures, it is a clean example of how an opt-out clause converts an approval into a specific, contracted-for payout rather than a future revenue estimate.

It is also the second time in as many years FDA has cleared a first-in-class therapy built on a genuinely novel mechanism rather than an incremental improvement on an existing drug class — a pattern regulatory teams have tracked closely across other rare-disease approvals this year, where the review question is less about safety margins on a familiar mechanism and more about whether the agency accepts an entirely new one.